Sign Out
Ampholip is indicated for the treatment of severe systemic and/or deep mycoses in cases where toxicity or renal failure precludes the use of conventional Amphotericin B in effective doses, and in cases where prior systemic antifungal therapy has failed. Fungal infections successfully treated with Ampholip include disseminated candidiasis and aspergillosis.
Ampholip has been used successfully in severely neutropenic patients.
Ampholip is not intended for use in common, clinically inapparent fungal diseases diagnosed only by skin tests or serological determinations.
Continue with Google